Michael J. Fox Foundation Commits up to $3 Million for Clinical Trials That Can Improve Treatment of Parkinson's Disease
“Trials to develop transformative treatments are not only scientifically and technically challenging but are often hampered by budgetary constraints that can limit the quality and quantity of data collected and therefore the interpretability of results,.” said
Ideal proposals will be rooted in well-designed and rigorous clinical trials that test potentially high-impact treatment approaches. Applicants may seek full support for a trial, if feasible within the program budgetary constraints, or may request funding to supplement a clinical testing effort supported by other funding sources. In the latter case, MJFF is particularly interested in assisting sponsors wishing to maximize data collected from clinical trials by the inclusion of additional trial features (e.g., increased sample size, inclusion/testing of additional or novel endpoints, increasing frequency of subject assessments or trial duration, etc.). Applicants should make a strong case for how the additional information can significantly improve the overall trial and lead to better decision making regarding continued clinical development of the tested therapeutic approach.
The program is open to academic and industry investigators alike and will provide up to $3 million in funding for clinical research projects for up to three years. Pre-proposals will be reviewed by the Foundation’s scientific staff and a panel of scientific experts and must be submitted online by
A conference call with MJFF Research Programs staff to further clarify the aims and goals of this initiative will be held March 11 at 12 p.m. U.S. Eastern Time. Researchers wishing to participate in the call must RSVP to email@example.com and will receive an e-mail reply with call-in details.